MedCity News July 1, 2024
Eli Lilly is paying $140 million for the exclusive right to buy Radionetics Oncology for the price of $1 billion. The clinical-stage startup, a Crinetics Pharmaceuticals spinout, develops radiopharmaceuticals that target GPCRs overexpressed by solid tumors.
Eli Lilly, fresh off of a billion-dollar acquisition that cemented its place in targeted radiation therapies, has inked another deal that positions it to stock up its pipeline of radiopharmaceuticals for cancer.
According to deal terms announced Monday, Lilly is paying $140 million for the exclusive right to acquire startup Radionetics Oncology. The Indianapolis-based pharmaceutical giant may exercise that right upon the conclusion of an exercise period, during which Radionetics will build up its pipeline of targeted radiation therapies. The length of the exercise...
Today's Sponsors
Today's Sponsor